EVOLVENCT06606340
A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
StatusEnrolling by Invitation
PhaseNot specified
SponsorSarepta Therapeutics, Inc.
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 9 words
- Primary endpoints: details revised at 1 of 6 entries
- Trial sites expanded: 20 → 23 locations
- Publications: details revised at 1 of 1 entry
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Loss of Ambulation (LOA)
Timeframe: Up to 5 years
Time to Rise From the Floor (Supine to Stand)
Timeframe: Up to 5 years
Time to Walk/Run 10 Meters
Timeframe: Up to 5 years
Performance of Upper Limb Module for DMD 2.0 (PUL 2.0) Entry Item A
Timeframe: Up to 5 years
Pulmonary Function, as Measured by Forced Vital Capacity (FVC) (% Predicted)
Timeframe: Up to 5 years
Cardiac Function, Including Left Ventricular Ejection Fraction (LVEF) as Measured by Echocardiogram (ECHO)
Timeframe: Up to 5 years
Arms and interventions
Eteplirsen
Golodirsen
Casimersen
Drugs: Eteplirsen, Golodirsen, Casimersen
Sites
23 sites in 1 country